# Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

> **NCT00136539** · PHASE2 · COMPLETED · sponsor: **Harold J. Burstein, MD, PhD** · enrollment: 41 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Herceptin
- **DRUG:** Taxol
- **DRUG:** Adriamycin
- **DRUG:** Cytoxan

## Key facts

- **NCT ID:** NCT00136539
- **Lead sponsor:** Harold J. Burstein, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2006-11
- **Final completion:** 2012-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-02-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136539, "Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00136539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*